{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'instance of corneal changes attributable to GSK2857916, end of study treatment visit, last', 'follow-up visit and as clinically indicated by the treating ophthalmologist:', '1.', 'Anterior segment OCT (optical coherence tomography)', '2.', 'Anterior segment/corneal slit lamp photography', '3.', 'Confocal microscopy (if available at the site)', '4.', 'Lissamine green staining', 'Given that these evaluations are exploratory, the treating ophthalmologist has the', 'discretion to perform them more frequently as they believe appropriate for the optimal', 'care of the individual participant. Representative images will be collected and stored', 'centrally.', '9.3.', 'Treatment of Overdose', 'There is no specific antidote for an overdose of GSK2857916. GSK does not recommend', 'a specific treatment for an overdose of GSK2857916.', 'In the event of an overdose of GSK2857916, the investigator must:', 'contact the GSK Medical Monitor immediately', 'monitor the participant closely for AEs/ SAEs and laboratory abnormalities until', 'GSK2857916 can no longer be detected systemically (at least 3 months).', '9.4.', 'Safety Assessments', 'Planned time points for all safety assessments are provided in the SOA (Table 1).', '9.4.1.', 'Physical Examinations', 'At screening, on dosing days, and at end of study treatment visit a full physical', 'examination will include assessments of the head, eyes, ears, nose, throat, skin, thyroid,', 'lungs, cardiovascular, abdomen (liver and spleen), lymph nodes, and extremities. Height', '(once at screening only) and weight must also be measured and recorded.', '9.4.2.', 'ECOG Performance Status', 'Participant performance status will be assessed at Screening, every 3 weeks starting at', 'Week 4 and End of Treatment using the Eastern Cooperative Oncology Group (ECOG)', 'scale, provided in Appendix 8.', '9.4.3.', 'Vital Signs', 'Vital sign measurements must include systolic and diastolic blood pressure, temperature,', 'and pulse rate. Vital signs must be measured after resting for at least 5 minutes. Vital', 'signs must be measured more frequently if warranted by the clinical condition of the', '82']['2017N330177_04', 'CONFIDENTIAL', '205678', 'participant. On days where vital signs are measured multiple times, temperature does not', 'need to be repeated unless clinically indicated.', '9.4.3.1.', 'First Infusion', 'Monitoring intervals: Vital signs must be monitored at designated time points related to', 'drug infusion as specified in the Schedule of Activities (Section 2). In general,', 'participants must also be monitored for at least 1 hour after the completion of the first', 'infusion and may be discharged if considered clinically stable and all other study', 'procedures have been completed.', '9.4.3.2.', 'Subsequent Infusions', 'Monitoring intervals: Vital signs must be monitored at designated time points related to', 'drug infusion as specified in the Schedule of Activities (Section 2). Participants may be', 'discharged after the infusion has been completed if considered clinically stable and all', 'other study procedures have been completed.', '9.4.4.', 'Electrocardiogram', '12-lead electrocardiogram (ECGs) must be obtained in triplicate at designated time points', 'specified in the Schedule of Activities (Section 2). The ECG machine must automatically', 'calculate the heart rate and measure PR, QRS, QT, and corrected QT (QTc) intervals. At', 'each assessment, a 12-lead ECG must be performed by qualified personnel at the site', 'after the participant has at least a 10-minute rest.', 'At each time point at which triplicate ECGs are required, 3 individual ECG tracings', 'should be obtained as closely as possible in succession, but no more than 2 minutes apart.', 'The full set of triplicate ECGs should be completed in 4 minutes or less.', \"The QT interval must be corrected for heart rate by Fridericia's formula (QTcF). Refer to\", 'Section 8.3 for QTc withdrawal criteria. Refer to the SRM for details regarding ECG', 'procedures.', '9.4.5.', 'Echocardiogram', 'Echocardiograms (ECHOs) must be performed at baseline to assess cardiac ejection', 'fraction for the purpose of study eligibility, as specified in the SOA. The evaluation of', 'the echocardiographer must include an evaluation for left ventricular ejection fraction', '(LVEF). If an ECHO is performed on study the results must be documented in the e-', 'CRF.', '9.4.6.', 'Laboratory Assessments', 'All protocol-required laboratory assessments, as defined in Table 14, must be performed', 'according to the SOA (Section 2). Details for the preparation and shipment of samples', 'for central laboratory assessments will be provided in the SRM.', 'The investigator must review the laboratory report, document this review, and record any', 'clinically relevant changes occurring during the study in the AE section of the CRF. The', '83']\n\n###\n\n", "completion": "END"}